Shilpa Medicare Ltd Q4 FY2026 Concall Summary

Key Takeaways

• Foundation year, not a breakout year: Revenue hit an all-time high and EBITDA margin expanded ~3pp to 29%, but management framed FY26 as building the base for the next decade rather than a peak.
• Formulations stole the show: The base formulation business (ex-licensing) grew 64% QoQ and 75% for the full year, with the European business more than doubling to over ₹200 crores.
• Biologics doubled, but the mix is opaque: ~100% YoY growth driven by CDMO deal momentum, yet management declined to break out the ₹150 crores revenue into CDMO, own biosimilars and licensing income.
• The pipeline is deep but distant: Nivolumab, an ADC biosimilar and two NBE programs enter human studies in FY27, but commercial revenues from Europe and ROW are not expected until FY29.
• What to watch next quarter: Whether the OLC dedicated block ships validation batches on schedule, the EMA response on Nivolumab, and any sign that the reinstated ₹18 crore associate profit from Maaia is recurring.

The Foundation-Year Framing

Management explicitly positioned FY26 as a year when the foundation for the next decade was laid, not a year of peak financial performance. The quarter delivered record revenue and margin expansion, but the emphasis was on capacity build-out, pipeline progression and manufacturing capability creation that will convert to revenue in FY27 through FY29.

• Revenue and margin delivery: Highest ever quarterly and annual revenues, with EBITDA margin improving ~2pp YoY for the quarter (28%) and ~3pp for the full year (29%), driven by increased revenue from key verticals and positive operating leverage.
• Interest cost stabilized: Interest outgo reduced YoY and is now expected to remain at the current quarter run rate for the near future, as capex will be funded broadly via internal accruals.
• Associate profit reinstatement carries a caveat: The ₹18 crore profit from associate Maaia (35% stake) was recorded because Maaia showed significant improvement, allowing reinstatement of the entire investment value that had previously been written down to zero. Management cannot confirm if this performance is sustainable as they do not control the entity.

Keshav Bhutada: "There are certain years in company's journey where performance improves, and there are certain years where foundation for next decade is built. For Shilpa Medicare, FY26 has been one such year where we have built our foundation."

Formulations: The Growth Engine

The formulation division delivered 54% quarterly and 30% full-year growth, but the base business (excluding licensing income) grew far faster at 64% quarterly and 75% full-year. The European business was the standout, more than doubling to over ₹200 crores.

• European ramp has further to run: Rotigotine Transdermal Patch, Tadalafil oral disintegrating film, Axitinib and other products are slated for European launch in FY27, with Rotigotine expected to reach full potential by FY28 as substitution across markets will not take long once approved.
• U.S. formulation reset: Azacitidine was discontinued in the U.S. due to changed market dynamics, and the company is now focusing on super specialty products. Three commercial 505(b)(2) products are expected to grow volumes steadily QoQ.
• Licensing income floor: Licensing income is expected to remain in a similar range at least, providing a stable base beneath the base business growth.
• OLC contribution deferred: Management does not project any meaningful contribution from OLC in FY27, citing confidentiality around the partner's filing strategy and approval timeline.

Keshav Bhutada: "We don't project any meaningful contribution coming from OLC in FY27. When they will get approval, how is their filing strategy, many of these details, are confidential in nature."

Biologics & CDMO: The Long Game

Biologics revenue grew ~100% YoY, driven by continued deal momentum in the CDMO business. However, management declined to provide a revenue breakdown or specific growth guidance, and the commercial payoff from the pipeline is weighted toward FY29.

• CDMO is the current driver: CDMO revenues are primarily in API (₹110 crores full year) and biologics, with no CDMO contribution in licensing fee income. An oncology breakthrough molecule being serviced for an innovator is expected to become meaningful in FY28, though not larger than past peak numbers.
• Biosimilar pipeline entering the clinic: Nivolumab (human study approval received in India, scientific advice submitted to EMA), the first ADC biosimilar (development completed using own payload, linker and conjugation), and two NBE programs will all enter human Phase I studies in FY27.
• Commercial revenues are FY29 story: Nivolumab, an ADC product and two NBE products entering global studies in FY27 are expected to generate commercial revenues from Europe and ROW in FY29. Adalimumab Europe and ROW revenues also come in FY29.
• Aflibercept Europe abandoned unless a partner pays: The company has no current plan to enter the European market for Aflibercept because the study is very long and costly, and management feels they are late; they will only proceed if a partner is ready to invest in the clinical study.
• Albumin progressing toward the clinic: IMPD submission in Europe is planned for the first half of FY27, with batches ongoing from the new facility. The regulator typically takes 3-4 months for trial approval. India study approval is already received.

Keshav Bhutada: "Currently, there is no plan of going into Europe market because it's a very long study and very costly study, and we feel that we are late for Europe market. So we are not planning to go for this product until and unless there is some partner who is ready to invest in the clinical study."

API: Steady, Not Spectacular

API grew 16%, benefiting from improved uptake of key products from newly expanded capacities and strong captive demand from the finished formulation vertical. The vertical integration helped improve the overall margin profile.

• Mix shift underway: API is now 50% of total business, with formulations and biologics making up the other 50%.
• Oncology API expansion is for captive use: A new oncology block expansion is underway, expected to be completed by FY27, for 15+ new oncology APIs. Growth will be steady rather than steep, with the major contribution going to captive formulation rather than external sales.
• Semaglutide on the horizon: Validation batches were completed in Q4 FY26, and the DMF is expected to be ready by the first half of FY27. The main focus will be on the export market, with API launched by Shilpa and formulations launched via partners in various markets.

Pipeline: Depth Versus Immediacy

The quarter saw a flurry of regulatory and development milestones, but the revenue conversion timeline stretches across FY27 to FY29. The three novel products (NorUDCA, Ondansetron extended-release injection, Dutasteride) carry a cumulative ₹500-600 crores potential over 2-3 years, contingent on partner performance.

• ADC manufacturing integration is a differentiator: The company is building its own integrated suite covering mAb, payload, linker and conjugation. Management claims this will be one of its kind in India.
• NorUDCA trajectory depends on real-world data: The disease curability duration is 6 months, so management is waiting for more data from doctors and hospitals once the initial 6-month treatment cycles are completed before projecting the trajectory. [7-8]

Keshav Bhutada: "With that integrated manufacturing capability, it will be one of its kind in India."

Margins & Capital Allocation

EBITDA margin improved to 28% for the quarter and 29% for the full year, a ~2pp and ~3pp YoY expansion respectively. Management called 35% an ambitious target that is not immediately achievable.

• Capex funded internally: No significant capex growth is expected over last year, and spending will be funded broadly via internal accruals. Interest outgo has stabilized at the current quarter run rate.
• Investment philosophy is near-to-mid-term: Management stated that the company is not investing in anything long-term; all investments are expected to generate revenue in the near term and midterm.
• Polymer business is a slow burn: One commercial product added decent revenue in FY26, and scaling-up opportunities are being evaluated for FY27. Management sees good potential but acknowledges it takes time, with meaningful contribution a few years ahead.
• Jadcherla facility under cloud but no revenue impact: The facility received USFDA observations; compliance has been completed and the company is waiting for a reaudit. Management stated this will not have any impact on revenues.

Keshav Bhutada: "Shilpa as a company, principally, what we are doing is we are not investing into anything which is long term. So whatever investments we are doing, are going to have revenue generation in near term and midterm."

Guidance & Commitments

Key Metrics